Fibromyalgia is a cause of chronic pain, classified by the Internal Classification of
Diseases (ICD) as a primary chronic pain with specific diagnostic criteria established by the
American College of Rheumatology (ACR). No treatment to its complete cure is available at
this time, all treatments having as purpose pain relief and an improvement of quality of life
by combining pharmacologic and nonpharmacologic treatments. One of the mechanisms proposed in
fibromyalgia is the central sensitisation phenomenon, by which the central nervous system
becomes "hypersensitive" to nociceptive or non-nociceptive stimuli. The receptor involved in
this phenomenon is the N-methyl-D-aspartate receptor to which ketamine binds. Ketamine has
therefore been proposed as a co-treatment in chronic pain with central sensitization
phenomena, such as fibromyalgia.